Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2660MR)

This product GTTS-WQ2660MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2660MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3647MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ8429MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ15257MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ13738MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ11365MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ7192MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ5967MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ11472MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEHD7945A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW